News

In the preclinical rodent study, donor adipose-derived stem and regenerative cells, or saline, was combined with donor adipose tissue and then transplanted onto recipient skulls. After six and

The comparison study assessed 465 patients with hormone receptor-positive breast cancer from a previous Eastern Cooperative Oncology Group (ECOG) study, computing both the Adjuvant Online risk estimate and

Duramed has initiated patent litigation in the US District Court of New Jersey seeking injunctive relief. Bruce Downey, chairman and CEO of Barr, said: “We believe that Watson’s

The new algorithm, which has been incorporated into Varian’s Eclipse treatment planning software, makes it possible to plan for intensity modulated proton therapy by optimizing dose distributions in

Kamada’s Transferrin has potential for utilization in the pharmaceutical industry as a targeting molecule for highly metabolizing cells with high iron requirement (cancerous or infected) cells. Kamada, which

The Japanese study was conducted over the course of a 20-month period, where a group of 15 amnestic mild cognitive impairment (MCI) patients with essential hypertension were divided

The 302 study for naproxcinod was initiated in April, 2007 and is being conducted by Premier Research Group. This study is a 53-week, randomized, double-blind, efficacy and safety

In the multi-center, open-label trial designed to investigate the activity of a short non-anthracycline-based preoperative treatment for early breast cancer in both HER2-negative and HER2-positive patients, promising results

The Committee for Medicinal Products for Human Use (CMPH) concluded that another study would be needed to demonstrate eprodisate’s (Kiacta) effectiveness. The company is currently reviewing all of